Welcome to Meta-IQ

Meta-IQ is a Danish biotech company that develops innovative treatment for CNS diseases including secondary progressive multiple sclerosis (SP-MS), acute ocular neuritis (AON), Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and depression  by inhibiting CPT1 (the key molecule in fat metabolism) and thus resetting the energy metabolism from fatty-acid back to glucose resulting in neuro-protective and anti-inflammatory properties. Meta-IQ has reached proof of concept in animal models for the small molecule compound MIQ-001. MIQ-001 is working via a new mode of action and has shown exceptional efficacy in these diseases, with findings independently confirmed by leading international researchers.

News and Events